Coherus BioSciences, Inc. (CHRS): A Bull Case Theory
We came across a bullish thesis on Coherus BioSciences, Inc. (CHRS) on Substack by Steve Wagner. In this article, we will summarize the bulls’ thesis on CHRS. Coherus BioSciences, Inc.
Coherus Biosciences Inc. (CHRS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Leucadia National Ian Cumming And Joseph Steinberg | 317,625 | $256,323 | +4% | 0% |
| 2. | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.42 | 3,700 | Officer | 35,118 | 2021-06-09 | Filing | |
| $13.50 | 425,926 | Director | 2,557,759 | 2014-11-12 | Filing | |
| $13.50 | 164,963 | Other | 3,042,019 | 2014-11-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.02 | 223,100 | 731,693 | 2023-11-22 | Filing | ||
| $16.80 | 3,507 | Officer | 31,611 | 2021-10-15 | Filing | |
| $16.12 | 286,076 | Director | 0 | 2021-09-29 | Filing | |
| $17.17 | 48,329 | Director | 286,076 | 2021-09-28 | Filing | |
| $18.06 | 100,150 | Director | 334,405 | 2021-09-27 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 58,249 | $57,375,032 | 2.22% | |
| 2. | 11,151,905 | $8,999,588 | 0% | |
| 3. | 10,978,359 | $8,859,535 | 0% | |
| 4. | 2,147,500 | $1,733,033 | 1.74% | |
| 5. | 991,513 | $800,151 | 0% |
News See All
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2024 Earnings Call Transcript
Operator: Hello everyone and welcome to the Coherus Fourth Quarter Year Ending 2024 Financial Results Conference call. At this time, all participants are in a listen-only mode.
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory
We came across a bullish thesis on Coherus BioSciences, Inc. (CHRS) on Substack by Steve Wagner. In this article, we will summarize the bulls’ thesis on CHRS. Coherus BioSciences, Inc.
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Q3 2024 Coherus BioSciences Earnings Conference Call. At this time, all participants are in a listen-only mode.
15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers
The U.S. Federal Reserve conducting a 50 basis point interest rate cut was the catalyst that stocks needed to bounce back from a period of stagnation.
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2024 Earnings Call Transcript
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2024 Earnings Call Transcript May 10, 2024.
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript
Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is $-0.62 EPS, expectations were $-0.21.
Here’s Why Aristotle Small Cap Equity Strategy Sold Coherus BioSciences (CHRS)
Aristotle Capital Boston, LLC, an investment advisor, released its “Small Cap Equity Strategy” fourth quarter 2023 investor letter. A copy of the same can be downloaded here.
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Coherus Biosciences Third Quarter 2023 Conference Call. At this time all participants are in a listen-only mode.
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q2 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Coherus Biosciences Second Quarter 2023 Conference Call. At this time all participants are in a listen-only mode.
Billionaire Hedge Funds
